Trevena Inc. (TRVN)

1.22
NASDAQ : Health Technology
Prev Close 1.17
Day Low/High 1.15 / 1.23
52 Wk Low/High 0.38 / 3.58
Avg Volume 1.58M
Exchange NASDAQ
Shares Outstanding 92.35M
Market Cap 108.05M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

3 Beaten-Down Biotechs That Should Head Up

3 Beaten-Down Biotechs That Should Head Up

Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.

2 Questions From the Biotech Mailbag

2 Questions From the Biotech Mailbag

A look at how lawsuits and FDA changes could impact the industry.

Why Cara Therapeutics Is Up, Trevena Down

Why Cara Therapeutics Is Up, Trevena Down

Readers want to know what to do with the two biotech names, which are headed in opposite directions.

What You Should Know About Trevena's New Painkiller

What You Should Know About Trevena's New Painkiller

Trevena's oliceridine seeks to provide the pain relief of morphine with less side effects.

Get Addicted to Trevena

Get Addicted to Trevena

This small-cap biopharma has a solid pipeline and a sound balance sheet.

Cara Therapeutics on a Run

Not much change in the market since our last update. The S&P 500 and Dow are down, and the NASDAQ is having a nice day. Longtime favorite Cara Therapeutics continues its huge run, up another 20% plus today. But I can't find any new news to support t...

Market Advantage Shifts to the Pessimists

Buyers don't have much staying power.

Neither Bears Nor Bulls Can Rejoice

The bears had a good opportunity early on but did nothing with it, though buyers gained little traction.

The Bulls Have No Place to Hide

The bears are locked and loaded.

Bulls Steadfast, but Market Players Skittish

Not a big day of gains, but there is underlying support.

Say What You Will, Bears: Price Action Is Good

Intraday dip buying is a good sign.

Trevena: Friday's Small-Cap Focus Stock

Trevena: Friday's Small-Cap Focus Stock

Small-cap biotech offers a big, promising pipeline.

Market Has a Mood Swing to the Upside

Gloom is gone as likelihood of Fed rate hike fades.

Flow of Bad News Pours Over Market

Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.

Late Buying Spurs Intraday Bounce

Mood improves, but there are still lots of reasons to worry.

'Sell the News' Reaction Is Quite Logical

After poor close on Thursday, market trends down all day.

Cutting Through the Fed Confusion

So where does the market go from here?

Market Gets Ahead of Fed Action

Today's strong action complicates the situation.

Sneaky Market Strength Has Nothing to Do With the Fed

Anxiety over being left behind is building.

Yawning All the Way to the Fed Decision

We have a few more days of this slow trading, and it is unlikely to change much.

Ugly Friday Finishes Off Last Week's Hope

Signs of support on the S&P, but there is a lot of uncertainty.